Characteristic of comparison groups
| Characteristic . | Observation (n = 94) . | AZA maintenance (n = 87) . |
|---|---|---|
| Age, median (range), y | 57.5 (20-75) | 57 (19-72) |
| Male sex, n (%) | 57 (60.6) | 51 (58.6) |
| MDS, n (%) | 25 (26.6) | 22 (25.3) |
| Cytogenetics, n (%) | ||
| Good risk | 15 (16) | 8 (9.2) |
| Intermediate risk | 42 (44.7) | 33 (37.9) |
| Poor risk | 37 (39.3) | 46 (52.9) |
| Disease status at HSCT, AML, n (%) | ||
| CR1/CR2 with count recovery | 23 (33.3) | 33 (50.8) |
| CR without count recovery | 7 (10.2) | 17 (26.2) |
| Active disease | 39 (56.5) | 15 (23) |
| Disease status at HSCT, MDS, n (%) | ||
| CR | 6 (24) | 4 (18.2) |
| Active disease | 19 (76) | 18 (81.8) |
| Hematopoietic stem cell source, n (%) | ||
| Bone marrow | 32 (34) | 31 (35.6) |
| PBSC | 60 (63.8) | 55 (63.2) |
| Cord blood | 2 (2.2) | 1 (1.2) |
| Donor type, n (%) | ||
| Matched related | 31 (33) | 33 (37.9) |
| Matched unrelated | 53 (56.4) | 44 (50.6) |
| Haploidentical | 5 (5.3) | 4 (4.6) |
| Reduced intensity conditioning | 18 (19.1) | 14 (16.1) |
| GVHD prophylaxis, n (%) | ||
| PTCy | 9 (9.5) | 4 (4.5) |
| Tacro/MTX | 82 (87.2) | 82 (94.2) |
| Tacro/MMF | 3 (3.2) | 1 (1.1) |
| HCT-CI, n (%) | ||
| 0-1 | 37 (39.4) | 28 (32.2) |
| 2-3 | 37 (39.4) | 22 (25.3) |
| ≥4 | 20 (21.3) | 37 (42.5) |
| Characteristic . | Observation (n = 94) . | AZA maintenance (n = 87) . |
|---|---|---|
| Age, median (range), y | 57.5 (20-75) | 57 (19-72) |
| Male sex, n (%) | 57 (60.6) | 51 (58.6) |
| MDS, n (%) | 25 (26.6) | 22 (25.3) |
| Cytogenetics, n (%) | ||
| Good risk | 15 (16) | 8 (9.2) |
| Intermediate risk | 42 (44.7) | 33 (37.9) |
| Poor risk | 37 (39.3) | 46 (52.9) |
| Disease status at HSCT, AML, n (%) | ||
| CR1/CR2 with count recovery | 23 (33.3) | 33 (50.8) |
| CR without count recovery | 7 (10.2) | 17 (26.2) |
| Active disease | 39 (56.5) | 15 (23) |
| Disease status at HSCT, MDS, n (%) | ||
| CR | 6 (24) | 4 (18.2) |
| Active disease | 19 (76) | 18 (81.8) |
| Hematopoietic stem cell source, n (%) | ||
| Bone marrow | 32 (34) | 31 (35.6) |
| PBSC | 60 (63.8) | 55 (63.2) |
| Cord blood | 2 (2.2) | 1 (1.2) |
| Donor type, n (%) | ||
| Matched related | 31 (33) | 33 (37.9) |
| Matched unrelated | 53 (56.4) | 44 (50.6) |
| Haploidentical | 5 (5.3) | 4 (4.6) |
| Reduced intensity conditioning | 18 (19.1) | 14 (16.1) |
| GVHD prophylaxis, n (%) | ||
| PTCy | 9 (9.5) | 4 (4.5) |
| Tacro/MTX | 82 (87.2) | 82 (94.2) |
| Tacro/MMF | 3 (3.2) | 1 (1.1) |
| HCT-CI, n (%) | ||
| 0-1 | 37 (39.4) | 28 (32.2) |
| 2-3 | 37 (39.4) | 22 (25.3) |
| ≥4 | 20 (21.3) | 37 (42.5) |
HCT-CI, hematopoietic comorbidity index; MTX, methotrexate; MMF, mycophenolate mofetil; PBSC, peripheral blood stem cell; PTCy, posttransplant cyclophosphamide.